한국지질동맥경화학회 학술대회

The joint symposium with the Japan Atherosclerosis Society (JAS) will explore cutting-edge advancements in incretin-based multi-agonist therapies for cardiometabolic disorders. Three distinguished speakers will share their expertise on this crucial topic. Professor Yasuo Terauchi from Yokohama City University, Japan, will discuss the efficacy and safety of tirzepatide, a GIP and GLP-1 dual agonist, in type 2 diabetes. Professor Chang Hee Jung from the University of Ulsan, Republic of Korea, will delve into the implications of GLP-1/GIP therapies for atherosclerotic cardiovascular disease (ASCVD). Professor Yong-ho Lee from Yonsei University, Republic of Korea, will elucidate the potential mechanisms underlying GLP-1/GIP therapies. This session promises to provide a comprehensive overview of the latest developments in multi-agonist therapies, their clinical applications, and their potential to revolutionize cardiometabolic disease treatment.

Recently, there has been a surge in efforts to find solutions to metabolic disease treatment strategies from adipose tissue biology, such as systematically establishing the hallmarks of adipose tissue dysfunction in the development of metabolic diseases. This session will focus on the latest research on the biological functions of adipose tissue and adipocytes, conducted from various perspectives. Professor Jae Myoung Suh from KAIST will present a study on new regulatory mechanisms of fuel metabolism in adipose tissue from RNA biology perspective. Professor Motoharu Awazawa from National Center for Global Health and Medicine (NCGM) will discuss the effects of new antidiabetic drugs on system-level metabolic physiology including adipose tissues. Professor Kae Won Cho from Soonchunhyang University (SIMS) will discuss the new pathophysiological roles of adipose dendritic cells in metabolic diseases.

Among the pathophysiological aspects of atherosclerosis, a traditionally overlooked factor is the biomechanical factors such as shear stress. This session aims to address these biomechanical factors. The first speaker, Professor Chang-Hoon Woo from Yeungnam University, will summarize the molecular biological mechanisms of how shear stress on endothelial cells is related to atherosclerosis. The second speaker, Professor Hanjoong Jo from Emory University, will present his recent achievements on flow-mediated reprogramming in endothelial cells. Finally, Professor Kwan Yong Lee from the Department of Cardiology at the Catholic University of Korea will introduce his research on how atherosclerosis progresses rapidly and develops into a disease through plaque and hemodynamic analysis in patients. This session is expected to help us understand and recognize the importance of the impact of biomechanical factors on atherosclerosis, which has been overlooked until now.

Dr. R. Scott Wright is a Professor of Medicine and a consultant in cardiology at the Mayo Clinic in Rochester. Dr. Wright focuses his research on acute coronary syndrome, dyslipidemia, type 2 diabetes, and valvular heart disease. He is a renowned international leader and an active clinical investigator of PRINCESS, CRISP and ORION programs. At ICoLA 2024, he will deliver a keynote lecture entitled, “Recent advances in the treatment of dyslipidemia with PCSK9 therapy and a look into potential new options in the next 10 years”.

In this special lecture, Professor Sung Nim Han from Seoul National University will deliver a lecture on the topic "Dissecting dietary approaches targeting lipid biomarkers." Professor Han, former president of the Korean Nutrition Society and the Korean Society of Clinical Nutrition, will systematically explore the impact of various dietary factors on lipid biomarkers. The lecture will include in-depth discussions on how dietary management affects lipid biomarkers in the bloodstream, contributing to a deeper understanding of its positive and negative impacts on health. Moreover, Professor Han will share insights based on extensive research experience and discuss future clinical application potential and vision.

The joint symposium with the Taiwan Society of Lipids & Atherosclerosis (TSLA) will delve into the pivotal role of remnant cholesterol in the statin era. We will explore its impact on cardiometabolic health, cardiovascular disease, and treatment options, with a focus on Asian populations. Professor Jun Hwa Hong from Eulji University will begin with "How does remnant cholesterol related to cardiometabolic multimorbidity" highlighting the links between remnant cholesterol and various cardiometabolic conditions. Next, Dr. Donna Shu-Han Lin from Shin Kong Wu Ho­Su Memorial Hospital will present "Epidemiologic evidence of hypertriglyceridemia or remnant cholesterol on cardiovascular disease" providing key epidemiological insights. Finally, Professor Youngwoo Jang from Gachon University will discuss "Treatments targeting remnant cholesterol or hypertriglyceridemia in Asians: do we have an option?" offering a detailed analysis of therapeutic strategies for Asian patients. Join us to gain a comprehensive understanding of remnant cholesterol in contemporary cardiovascular care.

This joint session is organized for academic exchange between the Korean Society of Lipid and Atherosclerosis (KSoLA) and the Society for Heart and Vascular Metabolism (SHVM). The first speaker, Professor Tae-Sik Park from Gachon University, will present on the role and regulatory mechanisms of S1P, a bioactive Iipid mediator and a sphingolipid metabolite, in NASH, based on his years of research. The second speaker, Professor Linda Peterson from Washington University, will discuss her research achievements on the role of ceramide, another sphingolipid metabolite, in cardiovascular diseases. The final speaker, Professor Helen E. Collins from the University of Louisville, will address the mechanisms of cardiac changes during pregnancy, a somewhat different topic. We hope that this session will help in understanding new risk factors and mechanisms in various diseases and physiological changes.

Atherosclerosis is a well-known inflammatory cardiovascular disease involving various immune cells. This session aims to discuss the latest research on the role of innate immune cells, which are crucial in the progression of atherosclerosis. Professor Andreas Zirlik from Medical University of Graz will present the latest insights on innate immune markers related to cardiovascular diseases. Professor Yeonseok Chung from Seoul National University will share his recent findings on the lipid metabolism­ related inflammatory mechanisms of dendritic cells, one of the key innate immune cells. Professor Christoph J. Binder from Medical University of Vienna will discuss the role of extracellular vesicles in the pathogenesis of atherothrombosis, and finally, Professor Andrew Murphy from the Baker Heart and Diabetes Institute will present the latest insights on hematopoiesis-related pathogenesis in atherosclerosis.

This session will discuss novel therapeutic targets in atherosclerosis. The first lecture will introduce gene editing technology for treating dyslipidemia and atherosclerosis, presented by Professor Giuseppe Danilo Norata from the University of Milan. Following this, Professor Jin Won Kim from Korea University will present targeted treatment strategies for atherosclerotic plaque using intravascular imaging. Lastly, Professor Alberico L. Catapano from the University of Milan and IRCCS Multimedica will deliver a lecture about the LDL burden for cardiovascular prevention. This session aims to present the latest research and innovative therapeutic approaches for patients with atherosclerosis.